INTRODUCTION
Acetylcholine and its projections from the basal forebrain/nucleus basalis magnocellularis and the medial septum (basal forebrain cholinergic complex) to the cerebral cortex and hippocampus are known to play major roles in memory functions, arousal and attentional processes (Fibiger, 1991; Gold, 2003) . In addition, acetylcholine, especially by interacting with dopamine, appears to participate in reward processes (Mansvelder et al., 2003; Cragg, 2006) . In the brain, acetylcholine activates two main types of cholinergic receptors, nicotinic receptors and muscarinic receptors. Nicotinic receptors are ion-gated channels (Wonnacott et al., 2005) while muscarinic receptors are G-protein coupled receptors (van der Zee and Luiten, 1999) . Although their localizations, modes of action and signaling cascades may differ, nicotinic and muscarinic receptors appear to be similarly implicated in the central effects of acetylcholine.
Cannabis is the most commonly used illegal drug of abuse in western countries. Acute intoxication with cannabis produces euphoria which is accompanied by impairment of cognitive functions (Goodman and Gilman, 2006) . Although these effects of cannabis are believed to be, at least in part, mediated by the cholinergic system, cannabinoid receptor agonists may disrupt performance in a working memory task through non-cholinergic mechanisms (Lichtman and Martin, 1996) . Cannabinoid and cholinergic systems may interact not only in brain systems involved in memory, such as the hippocampus (Kesner and Hopkins, 2006) , but also in brain systems involved in reward, such as the striatum (Di Chiara, 1999) , where both nicotinic and cannabinoid CB 1 receptors are localized (Martin and Aceto, 1981; Herkenham et al., 1991) .
The in-vitro effects of cannabinoid CB 1 receptor agonists on cholinergic neurotransmission have been well characterized in hippocampal slices, where they decrease long-term potentiation and depression, and inhibit the release of acetylcholine (Schlicker and Kathmann, JPET #116830 5 2001) . However, conflicting reports of the effects of cannabinoid CB 1 receptor agonists on hippocampal acetylcholine have been reported using in-vivo procedures (Gessa et al., 1998; Acquas et al., 2001; Tzavara et al., 2003; Pisanu et al., 2006) . For example, Gessa and colleagues reported that administration of the natural cannabinoid CB 1 receptor agonist delta-9-tetrahydrocannabinol, (THC) or the synthetic CB 1 receptor agonist WIN55,212-2 attenuated hippocampal efflux of acetylcholine (Gessa et al., 1998) , while Di Chiara and colleagues (Acquas et al., 2001; Pisanu et al., 2006) reported stimulation of hippocampal efflux of acetylcholine with the same compounds. In a recent paper, it was suggested that such conflicting findings could be dose-related, with high depressant doses of cannabinoid CB 1 receptor agonists acting predominately in the hippocampus to decrease cholinergic neurotransmission and with low activating doses of CB 1 receptor agonists acting predominantly in the septum to increase cholinergic neurotransmission (Tzavara et al., 2003) .
Given these contradictory results it is important to investigate whether behavioral effects of THC related to its abuse can be mediated or modulated by the cholinergic system and whether activation of the cholinergic system facilitates or antagonizes these effects of THC. Drugdiscrimination procedures allow for the study of the mechanisms through which drugs of abuse produce central effects that may contribute to the maintenance of drug-taking and serve as preclinical animal models for subjective reports of drug effects by humans . Although drug-discrimination techniques have been used for decades to investigate the effects of THC (see Wiley, 1999, for review) , no study has systematically investigated the involvement of the cholinergic system in the discriminative effects of THC.
In this study, rats learned to discriminate injections of THC from injections of vehicle and were then tested with drugs acting at nicotinic and muscarinic receptors in order to determine whether or not there was significant cholinergic modulation of the discriminative-stimulus JPET #116830 6 effects of THC. We also tested whether or not release of the endogenous cannabinoid anandamide could be involved in any modulation observed.
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METHODS
Subjects. Male Sprague-Dawley rats initially weighing 350-380 g (Charles River, Wilmington, Mass., USA) were housed individually. Rats' weights were gradually reduced to approximately 85% of free feeding by limiting daily access to food before the start of drugdiscrimination procedures. Once drug-discrimination training was started, weight was maintained at about 85% of free feeding by giving 15 g of food pellets shortly after the end of each daily session. Water was available ad libitum. All rats were housed individually in a temperature-and humidity-controlled room and were maintained on a 12-hour light/dark cycle; the lights were on from 6:45 a.m. to 6:45 p.m. Experiments were conducted during the light phase. Animals used in this study were maintained in facilities fully accredited by the Drug-discrimination apparatus and procedure. Standard operant conditioning chambers (Coulbourn Instruments, Lehigh Valley, Pa., USA) were used. Each chamber contained two levers, separated by a recessed tray into which a pellet dispenser could deliver 45 mg food pellets (F0021; Bioserv, Frenchtown, N.J., USA). Each press of a lever with a force of 0.4 N through 1 mm was recorded as a response and was accompanied by an audible click. The operant-conditioning chambers were controlled by computers using the MED Associates MED-PC software package (Med Associates Inc., East Fairfield, Vt., USA). Rats were trained, as described previously (Solinas et al., 2003) , under a discrete-trial schedule of foodpellet delivery to respond on one lever after an injection of a training dose of 3 mg/kg THC and on the other lever after an injection of 1 ml/kg of THC vehicle. Injections of THC or JPET #116830 8 vehicle were given intraperitoneally (i.p.) 30 min before the start of the session. At the start of the session, a white house light was turned on and in its presence the rats were required to make ten consecutive responses (fixed-ratio 10 schedule of food delivery; FR10) on the lever appropriate to the pre-session treatment. The completion of ten consecutive responses on the correct lever produced delivery of a 45 mg food pellet and initiated a 45-s time-out during which lever-press responses had no programmed consequences and the chamber was dark.
Responses on the incorrect lever had no programmed consequences other than to reset the FR requirement on the correct lever. After each time-out, the white house light was again turned on and the next trial began. Each session ended after completion of 20 fixed-ratio trials or after 30 min elapsed, whichever occurred first.
Discrimination-training sessions were conducted 5 days per week under a double alternation schedule (i.e. DDVVDDVV etc., D=drug, THC; V=Vehicle). Training continued until there were eight consecutive sessions during which rats completed at least 90% of their responses during the session on the correct lever and no more than four responses occurred on the incorrect lever during the first trial. Test sessions were then initiated. Test sessions were identical to training sessions with the exception that ten consecutive responses on either one of the two levers ended the trial. Switching responding from one lever to the other lever reset the ratio requirement. In a test phase, a single alternation schedule was introduced and test sessions were usually conducted on Tuesdays and Fridays. Thus, a 2-week sequence starting on Monday was: DTVDTVTDVT (T=test). In this way, test sessions occurred with equal probability after saline and drug sessions. Test sessions were conducted only if the criterion of 90% accuracy and not more than four incorrect responses during the first trial was maintained in the two preceding training sessions. The first test sessions consisted of different doses of the training drug in order to establish a THC dose-response curve. Afterwards, tests with other compounds alone or in combination with THC began.
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Two measures were analyzed: 1) percentage of total lever-presses made on the THC lever, that gives a quantitative indication of whether the drug or combination of drugs tested produces discriminative effects similar to those of the 3 mg/kg training dose of THC; and 2) overall rate of lever-press responding, which gives an indication of any disruption of motor responses produced by the drug or combination of drugs tested. When rates of responding were significantly reduced compared to basal levels, administrations of higher doses of that specific drug or combination of drugs were normally avoided.
Drugs
Delta-9-tetrahydrocannabinol (THC) (National Institute on Drug Abuse, NIH, Rockville, Md., 10 this study. The highest dose that did not produce significant depression of rates of responding by itself was used. It should be noted that, with nicotine, a dose of 0.3 mg/kg was initially used for combination studies. However, because 0.3 mg/kg of nicotine in combination with THC produced significant disruption of responding, a lower 0.1 mg/kg of nicotine was subsequently used for the remainder of the study.
Data analysis
Discriminative-stimulus data were expressed as the percentage of the total responses on the two levers that were made during the test session on the THC-appropriate lever. Responserate data were expressed as responses per second averaged over the session, with responding during time-out periods not included in calculations. The data from sessions during which rats did not complete at least one fixed-ratio trial were excluded from analysis of drug-lever selection. All results are presented as group means (+SEM). Statistical analysis of the ability of compounds to produce generalization to the discriminative effects of the training dose of THC was done using one-way ANOVA for repeated measures in comparison with vehicle treatments, followed, when appropriate, by the Dunnett's post-hoc test. A probability value of p<0.05 was considered significant. ED50 values for each compound or combination were obtained by nonlinear regression analysis with a sigmoidal dose-response (variable slope) equation, using GraphPad Prism 3 software (GraphPAD Software, San Diego, CA, USA). The equation was:
with the bottom and top values kept constant at 0% and 100%, respectively. Curves were considered parallel when their slopes did not differ significantly and dose-response curves were considered significantly different when 95% confidence intervals of ED50 values did not overlap. In addition, shifts in dose-response curves were also analyzed by two-way ANOVA for repeated measures with dose and pre-treatment as factors, followed, when JPET #116830 11 appropriate, by Student-Newman-Keuls post-hoc test. Statistical analysis of the effect of any treatment on rates of responding was done using one-way ANOVA for repeated measures in comparison with vehicle treatment, followed, when appropriate, by the Dunnett's post-hoc test. A probability value of p<0.05 was considered significant.
RESULTS
Discrimination of THC and lack of generalization of nicotine and pilocarpine
Rats readily discriminated vehicle injections (0% THC-lever selection) from injections of 3 mg/kg of THC (100% THC-lever selection) and discrimination of THC was dose dependent (Fig.1A, upper ( Fig.2A, lower panel) . In addition, neither mecamylamine (3 mg/kg) nor scopolamine (0.03 mg/kg) shifted the dose-response curve for THC discrimination (Fig.2B, upper panel) . (Fig.3, upper panel) without significantly altering rates of responding (Fig.3, lower (Fig.3, upper panel) without significantly altering rates of responding (Fig.3, lower panel) . (Fig.4) .
Nicotine, but not pilocarpine, produces THC-like effects when degradation of the endocannabinoid anandamide is inhibited by URB-597
To further investigate the possibility that release of endocannabinoids could mediate nicotineand pilocaprine-induced potentiation of THC's effects, we investigated whether blockade of metabolic cleavage of the endogenous cannabinoid anandamide would result in nicotine or pilocarpine producing significant THC-like discriminative effects. URB-597 is a selective inhibitor of fatty acid amide hydrolase (FAAH) (Kathuria et al., 2003) , the main enzyme responsible for anandamide inactivation, and is a drug that has been proposed for clinical use as a new anxiolytic and antidepressant (Kathuria et al., 2003; Gobbi et al., 2006 
DISCUSSION
To our knowledge, this is the first study to investigate the effects of nicotine or nicotinic antagonists on the discriminative effects of THC. In an earlier study, the effects of some muscarinic compounds (pilocarpine, oxotremorine and atropine) on THC discrimination were investigated but no involvement of muscarinic receptors in the discriminative effects of THC was found (Browne and Weissman, 1981) . In that study, the acetylcholinesterase inhibitor physostigmine also did not produce THC-like discriminative effects and did not antagonize the discriminative effects of THC (Browne and Weissman, 1981) , but only a single dose of each cholinergic compound was studied and the ability of these single doses to antagonize the discriminative effects of THC were only studied with the training dose of THC. In the present experiments, we replicated the lack of THC-like discriminative effects of muscarinic antagonists and the failure of muscarinic antagonists to reduce the discriminative effects of the training dose of THC and extended these findings to a wide range of THC doses and to the nicotinic agonist nicotine and the nicotinic antagonist mecamylamine. Our results demonstrate that neither nicotinic nor muscarinic receptors mediate the discriminative effects of THC and confirm that the discriminative effects of THC are selectively mediated by cannabinoid CB 1 receptors (Wiley et al., 1999; Jarbe et al., 2001 : Solinas et al., 2003 . However, when we investigated whether nicotinic or muscarinic agonists could alter the the dose-response curve for THC discrimination, we found that both nicotinic and muscarinic agonists produce a clear potentiation of the discriminative effects of THC. This suggests that the cholinergic system is involved in the modulation of the discriminative effects of THC, with nicotinic and muscarinic activation having facilitating effects on THC discrimination.
The present findings are in agreement with previous findings that the reinforcing and anxiolytic effects of nicotine and THC, their ability to produce physical dependence, and their effects on expression of immediate early genes such as c-FOS, are synergistic (Valjent et al., JPET #116830 17 2002; Balerio et al., 2004; Balerio et al., 2006) . For example, when ineffective doses of nicotine and THC are given in combination in mice, they produce clear anxiolytic effects in the elevated plus maze (Balerio et al., 2006) and the light-dark box and induce significant place preferences in an unbiased place conditioning procedure . In addition, pharmacological or genetic ablation of cannabinoid CB 1 receptors results in decreased behavioral effects of nicotine, including elimination of nicotine-induced conditioned place preferences in mice (Castane et al., 2002) and rats (Le Foll and Goldberg, 2004 ) and suppression of intravenous nicotine self-administration behaviour in rats (Cohen et al., 2005) . Finally, the present results are in agreement with other in-vivo findings that low doses of cannabinoid agonists increase cholinergic neurotransmission in the hippocampus (Acquas et al., 2001; Pisanu et al., 2006) .
The present and previous findings of facilitation between cannabinoid and cholinergic systems are in contrast with data showing that cannabinoids inhibit acetylcholine release in vitro (Schlicker and Kathmann, 2001 ) and in vivo (Gessa et al., 1998) . It has recently been proposed that such discrepancies could be due to the fact that high depressant doses of CB 1 receptor agonists act predominately in the hippocampus and decrease cholinergic neurotransmission, while low activating doses of cannabinoid CB 1 receptor agonists act predominately in the septum and increase cholinergic neurotransmission (Tzavara et al., 2003) . Thus, it appears that our drug-discrimination paradigm is more suited for studying the effects of low activating doses of THC that produce behavioral activation and reward than for studying effects of high doses of THC that produce behavioral depression and aversion (Sanudo-Pena et al., 2000; Ghozland et al., 2002) . This would be consistent with our previous findings that the discriminative effects of THC depend on activation of mu-opioid receptors, which are involved in the rewarding effects of low doses of JPET #116830
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THC, but not of kappa-opioid receptors, which are involved in the depressant and aversive effects of high doses of THC (Ghozland et al., 2002) .
Based on our previous work, where opioid modulation of THC discrimination involved release of endogenous beta-endorphin (Solinas et al., 2004) , we initially hypothesized that the present cholinergic potentiation of THC's effects was related to the ability of THC to release acetylcholine. If this were true, release of acetylcholine by CB 1 receptor activation and the consequent stimulation of nicotinic and muscarinic cholinergic receptors, would be part of the complex discriminative-stimulus effects of THC and low doses of THC together with agonists at cholinergic receptors, would result in discriminative effects similar to those of higher doses of THC. However, such a mechanism predicts that blockade of cholinergic receptors should block part of the complex discriminative-stimulus effects of THC and result in a rightward shift of the dose-response curve for THC discrimination. In contrast, in the present study, neither nicotinic nor muscarinic antagonists shifted the dose-response curve for THC discrimination to the right, indicating that other mechanisms were responsible for cholinergic modulation of the discriminative effects of THC.
One mechanism that could account for the shift to the left of the dose-response curve for THC discrimination produced by nicotine and pilocarpine and for the lack of a shift to the right with the nicotinic and muscarinic antagonists would be release of endogenous cannabinoids, such as anandamide, by nicotine and pilocarpine. That is, activation of nicotinic or muscarinic receptors would trigger the formation and release of endogenous cannabinoids and the elevated levels of newly formed endogenous cannabinoids, although too low to produce THC discriminative effects themselves, would facilitate the discriminative effects of low doses of THC.
We have recently demonstrated that intravenous anandamide produces clear THC-like discriminative effects at non-depressant doses when its metabolic inactivation by FAAH enzymes is blocked by URB-597 (Solinas et al., 2007) . Our results demonstrate that release of endocannabinoids, especially anandamide, could mediate the nicotine-induced potentiation of THC discrimination in this study. In fact, the cannabinoid CB 1 receptor antagonist rimonabant reversed nicotine-induced potentiation of THC discriminative effects, suggesting that CB 1 receptors were responsible for nicotine-induced potentiation of THC discrimination. In addition, blockade of the metabolic inactivation of the endogenous cannabinoid anandamide by URB-597, resulted in significant THC-like discriminative effects of nicotine that were reversed by rimonabant, further suggesting that nicotine releases anandamide. Consistent with our results, it has been recently reported that rats chronically treated with nicotine show increased levels of anandamide (Gonzalez et al., 2002) . However, since chronic treatment with nicotine could be associated with tolerance or sensitization to the effects of subsequent nicotine administrations, further studies are needed to investigate direct effects of acute nicotine on brain levels of endogenous cannabinoids.
In contrast to the results with nicotine, release of anandamide did not appear to be involved in the present pilocarpine-induced facilitation of THC discrimination. A dose of rimonabant that completely antagonized the discriminative and reinforcing effects of THC in previous studies (Solinas et al., 2003; Solinas et al., 2004; Zangen et al., 2006) and reversed nicotine-induced potentiation of THC discrimination in the present study did not antagonize pilocarpineinduced potentiation of THC discrimination. In addition, even when FAAH enzymes were blocked by URB-597, pilocarpine did not produce THC-like effects, suggesting again that facilitation of THC discrimination by pilocarpine does not involve endogenous anandamide. Similar mechanisms have already been proposed for interactions between opioid and cannabinoid receptors (Berrendero et al., 2003; Kathmann et al., 2006) and it has been suggested that such mechanisms may also underlie in-vivo interactions between opioid and cannabinoid systems at the behavioral level (Solinas et al., 2003; Solinas et al., 2004; .
In conclusion, we found that both nicotinic and muscarinic cholinergic agonists can facilitate, 28 seconds (lower panels) averaged over the entire session. Abscissae: dose in mg/kg (log scale).
C= control values for 3 mg/kg THC alone. Results represent means±SEM from 9-11 rats.
When nonlinear regression analysis was used to obtain ED 50 values, the regression curves are shown. Dose-response curves were also analyzed by repeated measures ANOVA followed by post-hoc Dunnett's test: * and **: p<0.05 and p<0.01 compared to vehicle. Numbers in parentheses at higher doses indicate the number of rats that completed at least one fixed ratio during the session over the total number of rats in which the dose was tested. Dose-response curve data for THC are the same as shown in Figures 1, 3 and 4. 30 the number of rats that completed at least one fixed ratio during the session over the total number of rats in which the dose was tested. ED50s were calculated by non-linear regression analysis using a Sigmoidal dose-response curve with variable slope Nic= Nicotine; Piloc=Pilocarpine; Mecam=Mecamylamine; Scopol=Scopalamine, Rim=Rimonabant ¶ Refers to the highest dose tested * Significantly different compared to THC alone
